RECELL for stable vitiligo: procedure, evidence, risks, and access

RECELL is a single-use device that processes a small sample of a person’s pigmented skin into a mixed suspension containing melanocytes and other skin cells. A trained professional applies it to a vitiligo area prepared with an ablative laser. It is not cultured stem-cell therapy, gene therapy, or a stand-alone “cell spray” cure.⌁ Evidence⌁ Evidence⌁ Evidence

The FDA PMA-approved RECELL for repigmentation of stable depigmented vitiligo lesions in adults under defined professional-use conditions. I could not verify a current model-specific EU or UK vitiligo scope from a regulator-hosted certificate and instructions. So the US indication must not be transferred to those jurisdictions.⌁ Evidence⌁ Evidence

At week 24, 9 of 25 RECELL areas reached at least 80% repigmentation versus 0 of 25 matched controls. That was the pivotal within-person randomized study of 25 adults with stable focal, segmental, or generalized vitiligo. Fourteen of 25 RECELL areas, or 56%, reached more than 50% repigmentation versus 3 of 25 controls, or 12%. No studied area reached complete repigmentation.⌁ Evidence

RECELL is contraindicated for known hypersensitivity to trypsin or compound sodium lactate, also called Hartmann’s solution. The instructions also say skin-sample collection should not be used when there is known hypersensitivity to anesthetics, adrenaline or epinephrine, povidone-iodine, or chlorhexidine. The procedure adds a donor wound, ablative-laser resurfacing, anesthesia, dressings, and wound aftercare. Reported or labeled concerns include scarring, hypertrophic scarring, redness, itching, infection, Koebner phenomenon, worsening vitiligo, and limits for several body sites and populations. The Koebner phenomenon is the name for patches that develop where previously unaffected skin was injured. A procedure injures skin on purpose, at the donor site and at the treated one.⌁ Evidence⌁ Evidence⌁ Evidence

RECELL requires a trained procedural center, suitable stable patches and donor skin, laser capability, wound care, follow-up, and coordination of the complete package. Coverage and personal cost are center- and payer-specific; I found no authoritative national price that can stand in for a written estimate.⌁ Evidence⌁ Evidence

The pivotal RECELL area received ablative-laser preparation and both the RECELL and control areas later received narrowband UVB. The study therefore supports that complete procedural package versus narrowband UVB alone. It cannot isolate the effect of the cell suspension from laser preparation or establish equivalent results without aftercare phototherapy.⌁ Evidence⌁ Evidence

The study was small. It does not establish outcomes for children, active disease, lips, eyelids, palms, soles, every skin tone, every center, or long-term color match and durability. Patient stories may explain recovery and access burden, but they cannot establish typical benefit or procedural safety.⌁ Evidence⌁ Evidence

SteadySkin does not yet have a documented pattern of what RECELL patients describe, and no first-hand account from Ajith exists yet for this procedure. Rather than invent one, SteadySkin says so plainly. It will grow as reader accounts and a documented pattern come in.⌁ Evidence

Keep dated photos of both the donor site and the treated area as they heal, since the pivotal study measured its week-24 result against a starting photograph. Note any redness, swelling, drainage, or pain at either site. Get in touch with the center promptly if a new patch appears where skin was injured - the Koebner phenomenon - since that was one of the reported events. Note when dressings come off and when follow-up visits happen, since aftercare and later phototherapy were part of the studied package.⌁ Evidence⌁ Evidence